EGFR mutation subtype impacts efficacy of immune checkpoint inhibitors in non-small-cell lung cancer

被引:5
作者
Fruh, M. [1 ,2 ]
Peters, S. [3 ]
机构
[1] Cantonal Hosp St Gallen, Dept Med Hematol Oncol, St Gallen, Switzerland
[2] Univ Bern, Bern, Switzerland
[3] Univ Hosp Lausanne CHUV, Dept Med Oncol, Lausanne, Switzerland
关键词
OPEN-LABEL; PEMBROLIZUMAB; DOCETAXEL; PHASE-3;
D O I
10.1093/annonc/mdz185
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
引用
收藏
页码:1190 / 1192
页数:4
相关论文
共 31 条
[1]  
[Anonymous], 2018, Ann Oncol
[2]   Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer [J].
Borghaei, H. ;
Paz-Ares, L. ;
Horn, L. ;
Spigel, D. R. ;
Steins, M. ;
Ready, N. E. ;
Chow, L. Q. ;
Vokes, E. E. ;
Felip, E. ;
Holgado, E. ;
Barlesi, F. ;
Kohlhaeufl, M. ;
Arrieta, O. ;
Burgio, M. A. ;
Fayette, J. ;
Lena, H. ;
Poddubskaya, E. ;
Gerber, D. E. ;
Gettinger, S. N. ;
Rudin, C. M. ;
Rizvi, N. ;
Crino, L. ;
Blumenschein, G. R. ;
Antonia, S. J. ;
Dorange, C. ;
Harbison, C. T. ;
Finckenstein, F. Graf ;
Brahmer, J. R. .
NEW ENGLAND JOURNAL OF MEDICINE, 2015, 373 (17) :1627-1639
[3]   Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic [J].
Chan, T. A. ;
Yarchoan, M. ;
Jaffee, E. ;
Swanton, C. ;
Quezada, S. A. ;
Stenzinger, A. ;
Peters, S. .
ANNALS OF ONCOLOGY, 2019, 30 (01) :44-56
[4]   Comprehensive molecular profiling of lung adenocarcinoma [J].
Collisson, Eric A. ;
Campbell, Joshua D. ;
Brooks, Angela N. ;
Berger, Alice H. ;
Lee, William ;
Chmielecki, Juliann ;
Beer, David G. ;
Cope, Leslie ;
Creighton, Chad J. ;
Danilova, Ludmila ;
Ding, Li ;
Getz, Gad ;
Hammerman, Peter S. ;
Hayes, D. Neil ;
Hernandez, Bryan ;
Herman, James G. ;
Heymach, John V. ;
Jurisica, Igor ;
Kucherlapati, Raju ;
Kwiatkowski, David ;
Ladanyi, Marc ;
Robertson, Gordon ;
Schultz, Nikolaus ;
Shen, Ronglai ;
Sinha, Rileen ;
Sougnez, Carrie ;
Tsao, Ming-Sound ;
Travis, William D. ;
Weinstein, John N. ;
Wigle, Dennis A. ;
Wilkerson, Matthew D. ;
Chu, Andy ;
Cherniack, Andrew D. ;
Hadjipanayis, Angela ;
Rosenberg, Mara ;
Weisenberger, Daniel J. ;
Laird, Peter W. ;
Radenbaugh, Amie ;
Ma, Singer ;
Stuart, Joshua M. ;
Byers, Lauren Averett ;
Baylin, Stephen B. ;
Govindan, Ramaswamy ;
Meyerson, Matthew ;
Rosenberg, Mara ;
Gabriel, Stacey B. ;
Cibulskis, Kristian ;
Sougnez, Carrie ;
Kim, Jaegil ;
Stewart, Chip .
NATURE, 2014, 511 (7511) :543-550
[5]   Pan-tumor genomic biomarkers for PD-1 checkpoint blockade-based immunotherapy [J].
Cristescu, Razvan ;
Mogg, Robin ;
Ayers, Mark ;
Albright, Andrew ;
Murphy, Erin ;
Yearley, Jennifer ;
Sher, Xinwei ;
Liu, Xiao Qiao ;
Lu, Hongchao ;
Nebozhyn, Michael ;
Zhang, Chunsheng ;
Lunceford, Jared ;
Joe, Andrew ;
Cheng, Jonathan ;
Webber, Andrea L. ;
Ibrahim, Nageatte ;
Plimack, Elizabeth R. ;
Ott, Patrick A. ;
Seiwert, Tanguy ;
Ribas, Antoni ;
McClanahan, Terrill K. ;
Tomassini, Joanne E. ;
Loboda, Andrey ;
Kaufman, David .
SCIENCE, 2018, 362 (6411) :197-+
[6]   EGFR mutation correlates with uninflamed phenotype and weak immunogenicity, causing impaired response to PD-1 blockade in non-small cell lung cancer [J].
Dong, Zhong-Yi ;
Zhang, Jia-Tao ;
Liu, Si-Yang ;
Su, Jian ;
Zhang, Chao ;
Xie, Zhi ;
Zhou, Qing ;
Tu, Hai-Yan ;
Xu, Chong-Rui ;
Yan, Li-Xu ;
Li, Yu-Fa ;
Zhong, Wen-Zhao ;
Wu, Yi-Long .
ONCOIMMUNOLOGY, 2017, 6 (11)
[7]   EGFR Mutations and ALK Rearrangements Are Associated with Low Response Rates to PD-1 Pathway Blockade in Non-Small Cell Lung Cancer: A Retrospective Analysis [J].
Gainor, Justin F. ;
Shaw, Alice T. ;
Sequist, Lecia V. ;
Fu, Xiujun ;
Azzoli, Christopher G. ;
Piotrowska, Zofia ;
Huynh, Tiffany G. ;
Zhao, Ling ;
Fulton, Linnea ;
Schultz, Katherine R. ;
Howe, Emily ;
Farago, Anna F. ;
Sullivan, Ryan J. ;
Stone, James R. ;
Digumarthy, Subba ;
Moran, Teresa ;
Hata, Aaron N. ;
Yagi, Yukako ;
Yeap, Beow Y. ;
Engelman, Jeffrey A. ;
Mino-Kenudson, Mari .
CLINICAL CANCER RESEARCH, 2016, 22 (18) :4585-4593
[8]   Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study [J].
Garassino, Marina Chiara ;
Cho, Byoung-Chul ;
Kim, Joo-Hang ;
Mazieres, Julien ;
Vansteenkiste, Johan ;
Lena, Herve ;
Jaime, Jesus Corral ;
Gray, Jhanelle E. ;
Powderly, John ;
Chouaid, Christos ;
Bidoli, Paolo ;
Wheatley-Price, Paul ;
Park, Keunchil ;
Soo, Ross A. ;
Huang, Yifan ;
Wadsworth, Catherine ;
Dennis, Phillip A. ;
Rizvi, Naiyer A. .
LANCET ONCOLOGY, 2018, 19 (04) :521-536
[9]   Pembrolizumab for the Treatment of Non-Small-Cell Lung Cancer [J].
Garon, Edward B. ;
Rizvi, Naiyer A. ;
Hui, Rina ;
Leighl, Natasha ;
Balmanoukian, Ani S. ;
Eder, Joseph Paul ;
Patnaik, Amita ;
Aggarwal, Charu ;
Gubens, Matthew ;
Horn, Leora ;
Carcereny, Enric ;
Ahn, Myung-Ju ;
Felip, Enriqueta ;
Lee, Jong-Seok ;
Hellmann, Matthew D. ;
Hamid, Omid ;
Goldman, Jonathan W. ;
Soria, Jean-Charles ;
Dolled-Filhart, Marisa ;
Rutledge, Ruth Z. ;
Zhang, Jin ;
Lunceford, Jared K. ;
Rangwala, Reshma ;
Lubiniecki, Gregory M. ;
Roach, Charlotte ;
Emancipator, Kenneth ;
Gandhi, Leena .
NEW ENGLAND JOURNAL OF MEDICINE, 2015, 372 (21) :2018-2028
[10]   Nivolumab Plus Erlotinib in Patients With EGFR-Mutant Advanced NSCLC [J].
Gettinger, Scott ;
Hellmann, Matthew D. ;
Chow, Laura Q. M. ;
Borghaei, Hossein ;
Antonia, Scott ;
Brahmer, Julie R. ;
Goldman, Jonathan W. ;
Gerber, David E. ;
Juergens, Rosalyn A. ;
Shepherd, Frances A. ;
Laurie, Scott A. ;
Young, Tina C. ;
Li, Xuemei ;
Geese, William J. ;
Rizvi, Naiyer .
JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (09) :1363-1372